Immunai

Immunai is an AI-powered platform specifically designed for the biopharmaceutical industry to accelerate drug discovery and development. The platform helps companies make data-driven decisions by analyzing the immune system at a single-cell level. It processes clinical and preclinical samples to generate multiomic data, which forms the foundation for identifying novel drug targets and understanding disease mechanisms. The core value of Immunai lies in its ability to translate complex immune system data into actionable insights for therapeutic development.

What sets Immunai apart is its comprehensive approach that combines wet lab capabilities with advanced computational analysis. The platform uses cutting-edge machine learning to compute novel immune features and link them to treatment responses. It's augmented by AMICA, described as the world's largest immune-focused, harmonized single-cell database, which provides unprecedented analytical power. The workflow follows a clear five-step process: generating high-quality data, augmenting it with their extensive database, computing insights through machine learning, validating hypotheses functionally, and providing actionable recommendations.

The platform is specifically valuable for pharmaceutical companies and research institutions working on immunology-focused therapeutics. Real-world applications include partnerships like the one with AstraZeneca for inflammatory bowel disease target discovery and with Teva for vitiligo disease mechanism research. Immunai helps these organizations reduce development risks, make smarter choices about which drugs to advance, and ultimately bring effective treatments to market faster by providing deeper insights into how drugs interact with the immune system.